Introduction
The σ receptors were initially categorised as a subtype of opioid receptors, because the effects of a prototypical opioid agonist, SKF10, 047 (N-allylnormetazocine), were independent from those of other opioid receptor agonists [1] . It was later determined that σ receptors have unique binding sites that are different from those of other opioid receptors, and at least two subtypes (σ 1 and σ 2 ) were classified based on pharmacological criteria [2] . In 1996, the σ 1 receptor was successfully cloned and characterised as a protein of 233 amino acids with two transmembrane domains [3] . Although the σ 1 receptor is not homologous to any mammalian protein, it shows a 30% overlap with yeast D8-D7 sterol isomerase, also known as emopamilbinding protein (EBP) [4] . The σ 2 receptor has yet to be cloned.
The σ 1 receptors have been shown to act as ligand-regulated molecular chaperones in the endoplasmic reticulum (ER) [5] . It is the first molecular chaperone in which the activity was found to be regulated by synthetic compounds in a clear agonist-antagonist manner [5] . Very recently, the putative σ 2 binding site was identified as progesterone receptor membrane component 1 (PGRMC1) [6] . Similar to the σ 1 receptors, PGMRC1 sites were localised in the ER and mitochondria.
Endogenous ligands for the σ 1 and σ 2 receptors have not been fully identified, and those for the σ 1 receptor were first proposed to be neurosteroids, including pregnenolone sulphate and progesterone [7] .
The endogenous hallucinogenic trace amine N,N-dimethyltryptamine was recently found to be a potent endogenous ligand for the σ 1 receptor [8] . The σ 1 receptor has been implicated in cellular differentiation [12, 13] , neuroplasticity [14, 15] , neuroprotection [16, 17] and cognitive function in the brain [18] . Table 3 . Affinities of ifenprodil and its analogue eliprodil at σ receptors in the rat brain (modified from reference [32] ). As discussed above, several CNS drugs bind to σ 1 receptors that are involved in enhancing neuroplasticity and cognitive function. The unique properties of these CNS drugs may be explained by this potent σ 1 receptor agonism.
